Dr.Reddy's Laboratories has acquired Trigenesis Therapeutics Inc, a United States-based privately owned dermatology company, with a total investment outlay of $11 million.
This acquisition provides Dr.Reddy's with access to certain products and proprietary drug delivery technology platforms for developing a pipeline of differentiated drugs in the dermatology segment, a DRL release said.
Dr.Reddy's will make additional contractual payments during the course of development of the products and technology platforms and royalties on sales to Skye Pharma and SivaFoam LLC pursuant to the existing Trigenesis agreements, the release added.